Strategies for immunotherapy-related hepatotoxicity in liver cancer
10.3760/cma.j.cn501113-20230928-00129
- VernacularTitle:肝癌免疫治疗相关肝毒性的应对策略
- Author:
Yang ZHI
1
;
Yimin MAO
Author Information
1. 上海交通大学医学院附属仁济医院 上海市消化疾病研究所 上海市脂肪性肝病诊治研究中心，上海 200001
- Keywords:
Hepatocellular carcinoma;
Immunotherapy;
Liver injury;
Diagnosis;
Management
- From:
Chinese Journal of Hepatology
2023;31(11):1125-1128
- CountryChina
- Language:Chinese
-
Abstract:
The successful market availability of immune checkpoint inhibitors (ICIs) has brought revolutionary changes to the treatment of hepatocellular carcinoma (HCC). With the widespread application of ICIs in HCC patients, the impact or even termination of antitumor therapy due to ICIs hepatotoxicity is a clinical problem that must be faced. However, it is currently unclear whether there are differences in the occurrence and risk factors of ICI hepatotoxicity between HCC patients and other tumors. At the same time, the chronic liver disease that often accompanies HCC patients also poses great challenges to their diagnosis and management. Therefore, clinical physicians need to understand the coping strategies for ICIs hepatotoxicity so as to improve the benefit of immunotherapy for patients.
